title: Effects of preoperative oral beta blocker versus intraoperative nitroprusside or esmolol on quality of surgical field during tympanoplasty.
abstract: OBJECTIVE
  To determine whether orally administered atenolol provides an optimal surgical field in comparison to intravenous sodium nitroprusside or esmolol during tympanoplasty.
  
  
  METHODS
  Randomized, double-blinded study.
  
  
  METHODS
  Operating room in a university hospital.
  
  
  METHODS
  105 ASA physical status 1 and 2 adult patients undergoing tympanoplasty.
  
  
  METHODS
  Patients were randomized to three groups to receive either oral atenolol 50 mg twice daily for one day prior to surgery (Group I), intraoperative nitroprusside infusion (Group II), or intraoperative esmolol infusion (Group III).
  
  
  METHODS
  Quality of the operative field, mean arterial pressure, and heart rate were assessed. Blood gases, liver enzymes, cardiac troponin I, creatine kinase isoenzyme-MB release, blood urea nitrogen, and creatinine concentrations also were measured.
  
  
  RESULTS
  Time to achieve target surgical field was significantly reduced in the atenolol group versus the other groups (8.3 ± 3.2, 28.2 ± 6.4, and 17.2 ± 5.3 min, respectively). Heart rate significantly decreased in the atenolol and esmolol groups versus the nitroprusside group (P < 0.0001). Mean arterial pressure after extubation and frequency of rebound hypertension were comparable in the groups. No significant changes in cardiac enzymes, renal and hepatic function, or acid-base status were noted.
  
  
  CONCLUSIONS
  Although the three drugs are acceptable for obtaining an optimum surgical field, preoperative oral beta blocker appeared to be rapid in onset and was simpler to implement.
authors: Department of Anesthesiology, Tanta University Hospital, Faculty of Medicine, Tanta, 31527, Egypt. yasser.amr@gmail.com
authors: Yasser Mohamed
authors: YM
authors: Amr
authors: Sabry M
authors: SM
authors: Amin
mesh_terms: D000284:Administration, Oral; D058671:Adrenergic beta-1 Receptor Antagonists / Q000494:pharmacology; D000328:Adult; D001262:Atenolol / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006785:Hospitals, University; D006801:Humans; D006973:Hypertension / Q000209:etiology; D007262:Infusions, Intravenous; D007430:Intraoperative Care / Q000379:methods; D008297:Male; D008875:Middle Aged; D009599:Nitroprusside / Q000494:pharmacology*; D011300:Preoperative Care / Q000379:methods; D011412:Propanolamines / Q000494:pharmacology*; D014433:Tympanoplasty / Q000379:methods*; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D011412:Propanolamines; D014665:Vasodilator Agents; D009599:Nitroprusside; D001262:Atenolol; C036604:esmolol